Therapeutic promise and challenges of targeting DLL4/NOTCH1

Vascular Cell

Volumn 3, Issue , 2011, Pages

  Yan, Minhong ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DELTA LIKE LIGAND 4; DELTA LIKE LIGAND 4 ANTIBODY; GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR; NOTCH1 RECEPTOR; OMP 21M18; REGN 421; SEMAGACESTAT; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN ANTIBODY;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

HARNESS;

EID: 84855869440     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-3-17     Document Type: Review

References (39)

1. Structural basis for autoinhibition of Notch. Gordon WR, Vardar-Ulu D, Histen G, Sanchez-Irizarry C, Aster JC, Blacklow SC, Nat Struct Mol Biol 2007 14 295 300 10.1038/nsmb1227 17401372 (Pubitemid 46608349)
2. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G, Yancopoulos GD, Proc Natl Acad Sci USA 2004 101 15949 15954 10.1073/pnas.0407290101 15520367 (Pubitemid 39507907)
3. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D, Differentiation 2001 69 135 144 10.1046/j.1432-0436. 2001.690207.x 11798067 (Pubitemid 33755062)
4. Isolation and characterization of the notch ligand delta4. Rao PK, Dorsch M, Chickering T, Zheng G, Jiang C, Goodearl A, Kadesch T, McCarthy S, Exp Cell Res 2000 260 379 386 10.1006/excr.2000.5034 11035934
5. Dll4, a novel Notch ligand expressed in arterial endothelium. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA, Kintner CR, Stark KL, Genes Dev 2000 14 1313 1318 10837024 (Pubitemid 30397075)
6. Dosage-sensitive requirement for mouse Dll4 in artery development. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, Costa L, Henrique D, Rossant J, Genes Dev 2004 18 2474 2478 10.1101/gad.1239004 15466159 (Pubitemid 39362889)
7. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T, Genes Dev 2004 18 2469 2473 10.1101/gad.1239204 15466160 (Pubitemid 39362888)
8. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JAS, de Sauvage F, Plowman G, Yan M, Nature 2006 444 1083 1087 10.1038/nature05313 17183323 (Pubitemid 46018529)
9. Notch signaling is essential for vascular morphogenesis in mice. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL, Gridley T, Genes Dev 2000 14 1343 1352 10837027 (Pubitemid 30397078)
10. Essential role of endothelial Notch1 in angiogenesis. Limbourg FP, Takeshita K, Radtke F, Bronson RT, Chin MT, Liao JK, Circulation 2005 111 1826 1832 10.1161/01.CIR.0000160870.93058.DD 15809373 (Pubitemid 40525149)
11. Therapeutic antibody targeting of individual Notch receptors. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, Ridgway J, Schahin-Reed D, Dow GJ, Shelton A, Stawicki S, Watts RJ, Zhang J, Choy R, Howard P, Kadyk L, Yan M, Zha J, Callanhan CA, Hymowitz SG, Siebel CW, Nature 2010 464 1052 1057 10.1038/nature08878 20393564
12. Delta-like 4/Notch signaling and its therapeutic implications. Yan M, Plowman GD, Clin Cancer Res 2007 13 7243 7246 10.1158/1078-0432.CCR-07-1393 18094402
13. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Jakobsson L, Bentley K, Gerhardt H, Biochem Soc Trans 2009 37 1233 1236 10.1042/BST0371233 19909253
14. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, Rosewell I, Busse M, Thurston G, Medvinsky A, Schulte-Merker S, Gerhardt H, Nat Cell Biol 2010 12 943 953 10.1038/ncb2103 20871601
15. Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations. Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T, Cancer Res 2011 71 1520 1525 10.1158/0008-5472.CAN-10-2817 21193546
16. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Wang X, Clarke MF, Lewicki J, Gurney A, Cell Stem Cell 2009 5 168 177 10.1016/j.stem.2009.05.019 19664991
17. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G, Nature 2006 444 1032 1037 10.1038/nature05355 17183313 (Pubitemid 46018516)
18. Inhibition of Dll4 mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS, Blood 2007
19. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M, Sharma A, Kanamaru E, Borisenko V, Desilva DM, Suzuki A, Wang X, Shawber CJ, Kandel JJ, Yamashiro DJ, Kitajewski J, Cancer Res 2008 68 4727 4735 10.1158/0008-5472.CAN-07-6499 18559519
20. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL, Cancer Res 2007 67 11244 11253 10.1158/0008-5472.CAN-07-0969 18056450 (Pubitemid 350248550)
21. The shunt problem: control of functional shunting in normal and tumour vasculature. Pries AR, Hopfner M, le Noble F, Dewhirst MW, Secomb TW, Nat Rev Cancer 2010 10 587 593 10.1038/nrc2895 20631803
22. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Siekmann AF, Lawson ND, Nature 2007 445 781 784 10.1038/nature05577 17259972 (Pubitemid 46279717)
23. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Shih Ie M, Wang TL, Cancer Res 2007 67 1879 1882 10.1158/0008-5472.CAN-06-3958 17332312 (Pubitemid 46424200)
24. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H, Nature 2005 435 959 963 10.1038/nature03659 15959515 (Pubitemid 40896322)
25. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH, Zimber-Strobl U, Strobl LJ, Honjo T, Clevers H, Radtke F, EMBO Rep 2008 9 377 383 10.1038/embor.2008.7 18274550
26. Dll1- and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells. Pellegrinet L, Rodilla V, Liu Z, Chen S, Koch U, Espinosa L, Kaestner KH, Kopan R, Lewis J, Radtke F, Gastroenterology 2011 140 1230 1240 e1237 10.1053/j.gastro.2011.01.005 21238454
27. Chronic DLL4 blockade induces vascular neoplasms. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, Plowman GD, Nature 2010 463 6 7 10.1038/nature08751 20147986
28. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK, J Clin Oncol 2006 24 2065 2072 10.1200/JCO.2005.05.3074 16648507 (Pubitemid 46622116)
29. Notch nicked again. Osherovich L, SciBx 2011 4 1 2
30. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. Liu Z, Turkoz A, Jackson EN, Corbo JC, Engelbach JA, Garbow JR, Piwnica-Worms DR, Kopan R, J Clin Invest 2011 121 800 808 10.1172/JCI43114 21266774
31. Delta-like 4 is indispensable in thymic environment specific for T cell development. Hozumi K, Mailhos C, Negishi N, Hirano K, Yahata T, Ando K, Zuklys S, Hollander GA, Shima DT, Habu S, J Exp Med 2008 205 2507 2513 10.1084/jem.20080134 18824583
32. Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. Koch U, Fiorini E, Benedito R, Besseyrias V, Schuster-Gossler K, Pierres M, Manley NR, Duarte A, Macdonald HR, Radtke F, J Exp Med 2008 205 2515 2523 10.1084/jem.20080829 18824585
33. A First-In-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells in patients with advanced solid tumors. Smith D, Eisenberg P, Stagg R, Manikhas G, Pavlovskiy A, Sikic B, Kapoun A, Benner S, 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, Nov 16-19, 2010 Berlin, Germany 2010
34. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S, Am J Hypertens 2010 23 460 468 10.1038/ajh.2010.25 20186127
35. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR, Urology 2010 76 923 926 10.1016/j.urology.2010.04.025 20646741
36. Notch targeting 2.0. Aster JC, Blood 2009 113 6044 6045 10.1182/blood-2009-03-212829 19520812
37. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C, Nikov G, Krishnamoorthy V, Majumder PK, Kelliher MA, Blood 2009 113 6172 6181 10.1182/blood-2008-02-136762 19246562
38. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, Nat Med 2009 15 50 58 10.1038/nm.1900 19098907
39. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ, Curley SA, Abdalla EK, Ellis LM, Vauthey JN, Cancer 2007 110 2761 2767 10.1002/cncr.23099 17960603 (Pubitemid 350250347)